Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone.

The global Sandostatin LAR market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Sandostatin LAR volume and value at global level, regional level and company level. From a global perspective, this report represents overall Sandostatin LAR market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Sandostatin LAR in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Sandostatin LAR manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
500mcg
1000mcg
Other

Segment by Application
Tumors
Bleeding Esophageal Varices
Other